In February and June, Huadong Medicine (000963) officially announced that Sinclair, a British wholly-owned subsidiary of the company, recently announced the acquisition of a 100% stake in Viora, an energy source-based medical and aesthetic device company.
It is reported that Viora was established in 2005 and is headquartered in New York, USA. It is an international medical beauty company focusing on non-invasive and minimally invasive energy source equipment for medical beauty. It has innovative technologies such as CORE™, SVC™ and PCR™, and has the ability to use laser , Intense pulsed light and radio frequency, high pressure jet, microdermabrasion and other advanced product portfolio, providing high-quality, cost-effective non-invasive and minimally invasive solutions, product applications cover anti-aging, body and facial contouring and other fields. Viora has sales operations in more than 60 countries/regions around the world, with more than 10,000 institutional users worldwide.
At present, Viora mainly has 5 types of energy source medical and aesthetic equipment products on the market, including ReactionTM for body and face shaping, skin tightening, radio frequency (RF), intense pulsed light (IPL), laser (Laser), etc. The “V series” product of the medical and aesthetic multi-functional operation platform integrating the energy source, the EnerJet product using the JVR needle-free minimally invasive high-pressure jet technology, the diamond microdermabrasion device PristineTM, and the Ionwave™ electroporation introduction technology InfusionTM.
Huadong Medicine stated that it has initially formulated a market strategy in China based on Viora’s existing products. For example, its core product, ReactionTM, uses Viora’s multi-frequency radio frequency CORE™ technology and is equipped with 3 different treatment handles. It has been approved by the US FDA and obtained the National Medical Products Administration (NMPA) Class III medical device registration certificate in 2015. , After the completion of the Viora equity transfer, Huadong Medicine plans to quickly integrate ReactionTM into the domestic self-operated sales team and quickly carry out market promotion work.
It is worth mentioning that Huadong Medicine put forward the concept of “V Women Tech” for the first time, using the world‘s advanced medical beauty technology, focusing on the field of female technology nursing, and creating a high-end product pipeline. The acquired Viora V-series multi-functional integrated operation platform can be equipped with laser/radio frequency/intense pulsed light energy source types at the same time, which can provide comprehensive solutions for face and body, and realize a full range of care for female customers, including Beauty treatments for face, body and intimate areas. In addition, Viora has the industry-leading research and development strength of energy source equipment. For the field of professional women’s care, Viora has a rich reserve of products under development, and has covered professional equipment including women’s neck, chest and private parts, which are used for shaping and tightening of women’s body parts. It is expected to be launched in overseas markets after the second half of 2022.
Huadong Medicine stated that this transaction is another important global strategic layout of Sinclair in the field of medical beauty energy source equipment after the wholly-owned acquisition of Spanish energy source medical and cosmetic equipment company High Tech in February 2021. Viora’s existing technologies and products such as intense pulsed light, microdermabrasion, and high-pressure jet are effectively complementary to Sinclair’s EBD business product pipeline.
Huadong Medicine said that after the completion of the acquisition, the Spanish and Bulgarian teams of Sinclair EBD business will efficiently integrate with Viora’s existing management, production, R&D and other departments to further improve the efficiency of Sinclair EBD business operation and management. Viora’s good brand reputation in the US market, complete market service staffing, complete marketing management system and extensive market resources will also become an effective entry point for Sinclair EBD business to further expand the US market.
According to statistics, after the completion of this transaction, Huadong Medicine will have more than 30 products in the field of non-invasive + minimally invasive medical aesthetics worldwide, of which 20 products have been listed at home and abroad, and more than 10 global innovative products are under research. The product portfolio covers non-surgical mainstream medical and aesthetic fields such as facial filling, thread embedding, skin management, body shaping, hair removal, private repair, etc., and has formed a comprehensive product cluster. The number of products and coverage areas are at the forefront of the industry, and many of them have potential The products are expected to be launched for sale at home and abroad in 2022, which will bring new growth momentum to the company’s global medical beauty business.
Lu Liang, chairman of Huadong Medicine, said that Viora’s products have differentiated competitive advantages. This transaction further expands the company’s innovative product pipeline for medical aesthetics, which is in line with the company’s international development strategy for medical aesthetics, and helps to continuously consolidate and enhance the company’s medical aesthetics. comprehensive competitiveness in the United States. In the future, the company will continue to make steady progress in accordance with the established strategy of ‘global operation layout, dual-cycle operation and development’, strengthen the international industry expansion with the British wholly-owned subsidiary Sinclair as the global medical beauty operation center, and insist on independent research and development and external cooperation. and equity investment and other diversified business models, introduce world-class medical and aesthetic products with high scientific and technological value into China one after another, adhere to the self-operated model, rely on the company’s professional clinical registration and marketing team, and help the rapid development of international high-quality products. commercialization. Gradually realize the global strategic layout of the company’s medical aesthetics, and strive to build Sinclair into a world-class high-end innovative medical and aesthetic enterprise.Return to Sohu, see more
Editor:
Disclaimer: The opinions of this article only represent the author himself, Sohu is an information publishing platform, and Sohu only provides information storage space services.